



In re Application of:

GUSTAV GAUDERNACK, ET AL.

Application No.: 09/674,913

Filed: May 25, 2001

Int'l Appl. No.: PCT/NO99/00141

Int'l Appl. Filing Date: April 30, 1999

For: FRAMESHIFT MUTANTS OF  
BETA-AMYLOID PRECURSOR  
PROTEIN AND UBIQUITIN-B  
AND THEIR USE

41  
1647  
Docket No. 01702.401600

RECEIVED

SEP 02 2003

Examiner: Christopher Nichols, Ph.D.

Group Art Unit: 1647

Date: August 25, 2003

**Mail Stop Non-Fee Amendment**  
THE COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment in the above-identified application.

☒ No additional fee is required.


The fee has been calculated as shown below

CLAIMS AS AMENDED						
	(2) CLAIMS REMAINING AFTER AMENDMENT		(4) HIGHEST NO. PREVIOUSLY PAID FOR	(5) PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL CLAIMS	2	MINUS	66	= 0	x \$18	0
INDEP. CLAIMS	1	MINUS	1	= 0	x \$84	0
Fee for Multiple Dependent claims \$140°/\$280						
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT---						0

- \* If the entry in Column 2 is less than the entry in Column 4, write "0" in Column 5.
- \*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- \*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

- ☐ Verified Statement claiming small entity status is enclosed, if not filed previously.
- ☐ A check in the amount of \$\_\_\_\_\_ is enclosed.
- ☐ Charge \$\_\_\_\_\_ to Deposit Account No. 06-1205. A duplicate copy of this sheet is enclosed.
- ☒ Any prior general authorization to charge an issue fee under 37 C.F.R. 1.18 to Deposit Account No. 06-1205 is hereby revoked. The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. 1.16 and 1.17 which may be required during the entire pendency of this application, or to credit any overpayment, to Deposit Account No. 06-1205. A duplicate copy of this paper is enclosed.
- ☐ A check in the amount of \$\_\_\_\_\_ to cover the fee for a \_\_\_\_\_ month extension is enclosed.
- ☐ A check in the amount of \$\_\_\_\_\_ to cover the Information Disclosure Statement fee is enclosed.
- ☒ Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

  
John W. Behringer  
Registration No. 23,086  
Attorney for Applicants

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200

Form #120

DC\_MAIN 142281v1

01702.401600



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
GUSTAV GAUDERNACK, ET AL.	)	Examiner: Christopher Nichols, Ph.D.
Application No.: 09/674,913	)	Group Art Unit: 1647
Filing Date: May 25, 2001	)	
Int'l Appl. No.: PCT/NO99/00141	)	
Int'l Appl. Filing Date: April 30, 1999	)	
For: FRAMESHIFT MUTANTS OF	)	August 25, 2003
BETA-AMYLOID PRECURSOR	)	
PROTEIN AND UBIQUITIN-B	)	
AND THEIR USE	)	

**RECEIVED**  
SEP 02 2003  
TECH CENTER 1600/2900

**Mail Stop Non-Fee Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

AMENDMENT

Sir:

Introductory Comments

The present Amendment has been prepared in accordance with the Revised Format established by the U.S. Patent and Trademark Office, as permitted in the Pre-OG Notice entitled "Amendments in a Revised Format Now Permitted".

In response to the Office Action mailed June 2, 2003, the Examiner is requested to amend the above-identified application as follows.

IN THE TITLE

On page 1, lines 1 and 2, of the specification, please change the title of the invention from ~~FRAMESHIFT MUTANTS OF BETA-AMYLOID PRECURSOR PROTEIN AND UBIQUITIN- $\beta$  AND THEIR USE~~ to read IMMUNOGENIC BETA AMYLOID PEPTIDE so that it more clearly describes the invention to which the claims are directed.